Imricor Medical Systems Inc (ASX: IMR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imricor Medical Systems Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $633.87 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 320.95 million
Earnings per share -0.138
Dividend per share N/A
Year To Date Return 22.22%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Imricor Medical Systems Inc (ASX: IMR)
    Latest News

    Happy work colleagues give each other a fist pump.
    Share Gainers

    Why Appen, Imricor, Qoria, and Xero shares are storming higher today

    These shares are rising on Tuesday. But why?

    Read more »

    Bored man sitting at his desk with his laptop.
    Share Fallers

    Why Imricor, Ioneer, Star, and Whitehaven Coal shares are falling today

    These shares are ending the week in the red. But why?

    Read more »

    Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
    Share Gainers

    Why Appen, Imricor, Sunrise Metals, and Whitehaven Coal shares are charging higher today

    These shares are avoiding the market weakness on Thursday. But why?

    Read more »

    Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
    Healthcare Shares

    Guess which ASX stock is jumping 18% on FDA approval news

    Big news is getting investors excited on Thursday.

    Read more »

    A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
    Share Gainers

    Why Develop Global, Imricor Medical, Light & Wonder, and PWR shares are storming higher today

    These shares are having a strong start to the week. But why?

    Read more »

    Medical workers examine an xray or scan in a hospital laboratory.
    Healthcare Shares

    Which biotech company's shares have rocketed to a new high on good news?

    A key US approval is great news for this company.

    Read more »

    Stock market chart in green with a rising arrow symbolising a rising share price.
    Broker Notes

    Top brokers name 2 ASX All Ords stocks tipped to surge 67% and 69%

    Leading brokers expect material outperformance from these two ASX All Ords stocks.

    Read more »

    Surgeon looking at a monitor in an operating room.
    Share Market News

    Is the only way up for this ASX small-cap healthcare stock?

    Bigger returns could be coming for this ambitious small-cap.

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Gainers

    Why Domino's, DroneShield, Imricor, and Pepper Money shares are storming higher today

    These shares are avoiding the market weakness on Tuesday.

    Read more »

    a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
    Share Gainers

    Guess which ASX All Ords healthcare share is rocketing 14% on a 'world first' success

    Investors are piling into the ASX All Ords healthcare stock on Tuesday.

    Read more »

    Concept image of a businessman riding a bull on an upwards arrow.
    Broker Notes

    This ASX All Ords healthcare share more than doubled investors' money in a year. Here's why it's tipped to rocket another 55%

    A leading broker forecasts another year of strong outperformance for this surging ASX All Ords healthcare stock.

    Read more »

    Ecstatic woman looking at her phone outside with her fist pumped.
    Share Gainers

    Why DroneShield, Imricor, Paladin Energy, and Silex shares are pushing higher

    These shares are avoiding the market weakness and are pushing higher.

    Read more »

    IMR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imricor Medical Systems Inc

    Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe, followed by the Middle East and the United States.

    IMR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    09 Feb 2026 $1.91 $0.04 2.14% 68,240 $1.90 $1.97 $1.87
    06 Feb 2026 $1.87 $-0.05 -2.60% 150,193 $1.96 $1.96 $1.82
    05 Feb 2026 $1.92 $0.01 0.52% 134,167 $1.98 $1.98 $1.88
    04 Feb 2026 $1.91 $-0.12 -5.91% 37,490 $1.99 $1.99 $1.90
    03 Feb 2026 $2.03 $0.08 4.10% 54,172 $1.99 $2.04 $1.98
    02 Feb 2026 $1.95 $-0.03 -1.52% 394,343 $2.03 $2.12 $1.90
    30 Jan 2026 $1.98 $-0.07 -3.41% 1,000,989 $1.99 $2.06 $1.94
    29 Jan 2026 $2.05 $0.19 10.24% 1,307,035 $2.12 $2.25 $1.89
    28 Jan 2026 $1.86 $-0.04 -2.11% 162,103 $1.95 $1.95 $1.82
    27 Jan 2026 $1.90 $-0.10 -5.00% 171,730 $2.00 $2.03 $1.90
    23 Jan 2026 $2.00 $-0.02 -0.99% 52,365 $2.01 $2.02 $1.98
    22 Jan 2026 $2.02 $-0.02 -0.98% 266,061 $2.04 $2.04 $1.96
    21 Jan 2026 $2.04 $0.02 0.99% 305,785 $2.02 $2.04 $1.95
    20 Jan 2026 $2.02 $0.06 3.07% 289,856 $1.99 $2.04 $1.91
    19 Jan 2026 $1.96 $0.08 4.26% 374,947 $1.92 $2.04 $1.89
    16 Jan 2026 $1.88 $0.03 1.63% 164,134 $1.85 $1.95 $1.82
    15 Jan 2026 $1.85 $-0.01 -0.54% 75,685 $1.88 $1.88 $1.82
    14 Jan 2026 $1.85 $0.03 1.65% 162,015 $1.89 $1.89 $1.78
    13 Jan 2026 $1.82 $-0.03 -1.62% 205,620 $1.95 $1.96 $1.80

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Jun 2025 Mark Tibbles Transfer 73,380 $80,000
    Off-market transfer. usd$
    05 Jun 2025 Mark Tibbles Sell 170,000 $286,360
    On-market trade. CDIs
    04 Jun 2025 Steve Wedan Issued 955,893 $1,591,561
    Issue of options.
    20 May 2025 Mark Tibbles Issued 41,280 $66,460
    Issue of securities. CDIs, Non cash
    20 May 2025 Anita Messal Issued 38,700 $62,307
    Issue of securities. CDIs, non cash
    20 May 2025 Peter McGregor Issued 41,280 $66,460
    Issue of securities. Non cash issue, CDIs

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Peter McGregor Non-Executive Director May 2019
    Mr McGregor has over 30 years of experience in senior finance and management roles, including having been a partner in the investment banking firm of Goldman Sachs JBWere and a managing director in the institutional banking & markets division of Commonwealth Bank of Australia. Mr McGregor is an experienced company director, and currently serves as a Director of Treasury Corporation of Victoria and Green Eco International Limited, and is a former director of TRUE Infrastructure Management Pty Ltd, and the Brisbane Lions Australian Football Club. He is chair of the Risk Committee.
    Mr Steve Wedan Chief Executive OfficerPresidentExecutive ChairmanExecutive Director May 2006
    Mr Wedan has over 30 years of experience in the medical device industry including design engineering of MRI and ultrasound systems for GE Healthcare, as well as Vice President and Chief Technology Officer for Applied Biometrics Inc. Immediately prior to co-founding Imricor, Mr Wedan founded and operated a technical consulting company, Wedan Technologies Inc., from 2000-2006. Mr Wedan is a member of international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI. Mr Wedan currently serves on the Board of Directors of Medical Device Research Forum, Inc. and Water Rescue Innovations, Inc., as well as the Advisory Board of Poiesis Medical, LLC.
    Mr Mark Tibbles Non-Executive Deputy ChairmanNon-Executive Director Sep 2014
    Mr Tibbles is an entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies. Mr Tibbles is currently a Board member of FamGenix, and CorVent Medical, Inc.; Co-Founder and Board member of PERMnet, Inc.; an owner and managing member of STEM Fuse, LLC, one of the providers of digital K-12 STEM curriculum in the U.S.; and the Managing Director of Strategic Stage Ventures, LLC. Prior to his current roles, Mr Tibbles was a Board member of the Nerdery, LLC as well as an owner and member of Intuitive Technology Group until it was sold in 2017. Mr Tibbles was also a President and founder of PRC Consulting, Inc., a company in the management and implementation of IT projects for Fortune 1000 Companies, from 1998 until 2013, when PRC was sold. He is member of the Risk Committee.
    Ms Anita Messal Non-Executive Director Mar 2021
    Ms Messal is an executive with 40 years of accomplishments across a variety of functions. With a career in healthcare and benefits, she has experience in health plan services, health care delivery, care management, and benefits administration. Ms Messal has experience in public, private, and non-profit sectors, working in both domestic and international markets. She has led areas of company performance, including sales, product, operations, and technology. Her responsibilities have encompassed M&A integration, data exchange, account management, customer service, system development, information security, product development, national accounts, project management, vendor management, strategic systems, legal, human resources, and learning & development. Ms Messal has also played a role in fundraising from start-up through IPO and sale to strategic buyers and private equity. Ms Messal currently serves on the Board of Directors of Ideon as Executive Chair and is an Advisor to Poiesis Medical. She is member of the Risk Committee.
    Mr Jeffrey Leighton Non-Executive Director Jul 2024
    Dr Leighton is a cognitive neuroscientist with experience in both academic and corporate settings. He has a robust research, teaching, and leadership background. Dr Leighton has business acumen as CFO at NDS Wellness, a regional (23 states) provider of mobile neuroimaging and wellness centers. He was in the company's growth phase, managing financial operations and working with the CEO. NDS Wellness offered comprehensive services, including mobile wellness clinics, telehealth, and health screenings, to corporations and self-insured companies. Dr Leighton has held key corporate governance and advisory roles, including serving as an Institutional Review Board (IRB) member at a non-profit neuromodulatory research center.
    Mr Aldo Denti Non-Executive Director Nov 2025
    Mr Denti has 30 years of global experience in the medical device industry. Mr Denti recently left his role as Company Group Chairman of Global Orthopaedics for Johnson & Johnson MedTech. Mr Dentis other experiences include various Sales and Marketing roles with companies such as DePuy, Medtronic, and Pfizer. On October 6th, 2025, Mr Denti joined Dentsply Sirona, as its Chief Commercial Officer.
    Mr Kobe Li Company Secretary
    -
    Gregg Stenzel Chief Operating Officer
    -
    Kobe Li Company Secretary
    -
    Nick Corkill Vice President Corporate Strategy
    -
    Kate Lindborg Vice President of Clinical Affairs
    -
    Jonathon Gut Vice President of Finance and Chief Financial Officer
    -
    Greg Englehardt Vice President of Global Sales
    -
    Nick Twohy Vice President of Marketing and Business Development
    -
    Vic Fabano Vice President of Operations
    -
    Jennifer Weisz Vice President of Regulatory and Quality
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited <Domestic Hin A/C> 56,359,497 17.59%
    HSBC Custody Nominees (Australia) Limited 44,330,815 13.84%
    BNP Paribas Noms (Nz) Ltd 17,075,876 5.33%
    J P Morgan Nominees Australia Pty Limited 15,569,712 4.86%
    Argo Investments Limited 11,238,407 3.51%
    Warren G Herreid Ii 9,486,098 2.96%
    Siemens Medical Solutions Usa Inc 8,384,150 2.62%
    UBS Nominees Pty Ltd 7,742,928 2.42%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 7,409,555 2.31%
    HR Global Investments Llc 6,879,579 2.15%
    HSBC Custody Nominees (Australia) Limited A/C 2 5,680,400 1.77%
    Kahr Foundation 2,950,988 0.92%
    Mr Grant Bruce Byron Taylor and Mr Keith Robert Taylor <Sorrento A/C> 2,732,000 0.85%
    Steven R Wedan 2,693,720 0.84%
    Maclay Group Pty Ltd <Maclay Longhurst Family A/C> 2,662,178 0.83%
    Mr Kenneth Joseph Hall <Hall Park A/C> 1,923,077 0.60%
    Pounamu Capital Pty Limited 1,923,077 0.60%
    BNP Paribas Noms Pty Ltd 1,862,834 0.58%
    Merrill Lynch (Australia) Nominees Pty Limited 1,813,512 0.57%
    Bauer Private Equity Fund Vi Llc 1,696,555 0.53%

    Profile

    since

    Note